A kind of resveratrol solid lipid nanoparticle and preparation method thereof

Abstract

The invention relates to a resveratrol solid lipid nanoparticle and a preparation method thereof. The preparation method comprises the following steps: a) taking resveratrol, an emulsifier and a lipid material, heating and melting the lipid material and mixing it with the emulsifier and resveratrol, then add an organic solvent, and mix to obtain an oil phase; b) place the oil phase in a container and evaporate to dryness under reduced pressure to obtain an oil film, place the water phase in the container, and Place in an ultrasonic cleaner with an ultrasonic power of 40-60KHz and process for 30-60 minutes to obtain resveratrol solid lipid nanoparticles. The resveratrol solid lipid nanoparticle prepared by the invention has the advantages of small particle size, high drug loading capacity, fast drug absorption, high bioavailability, convenient administration, low toxicity, etc., and has strong practicability.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a resveratrol solid lipid nanoparticle and a preparation method thereof. Background technique [0002] Many studies have reported that resveratrol (Resveratrol, Res) is a polyphenolic compound that has pharmacological effects such as lowering blood lipids, protecting cardiovascular, anti-tumor, and anti-oxidation. Studies have found that resveratrol also has the ability to inhibit the release of calcium stores. Calcium ions thus inhibit platelet activity and play a role in inhibiting platelet aggregation. Resveratrol has strong polarity, is difficult to dissolve in water, and is easily soluble in strong polar solvents such as chloroform, methanol, ethanol, acetone, etc. It has low oral bioavailability and is unstable to light. inconvenient. Solid Lipid Nanopartieles (SLN) is a solid micelle drug delivery system made by using physiologically compatible high-melting point lipid ...

AI Technical Summary

Problems solved by technology

Wherein, wine agent (public patent No. CN1472303) is suitable for a smaller crowd, injection (public patent No. CN102188370A) has poor patient compliance, and phospholipid complex (public patent No. CN101095664) has poor stability, so the above dosage forms are not suitable for clinical use

Liposome (public patent No. CN102757555A) has a complicated preparation process and is not suitable for large-scale industrial production, so it is also not suitable for clinical use

[0004] There is no report about resveratrol solid lipid nanoparticles

Images